Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation.
The addition of bevacizumab to weekly paclitaxel as primary chemotherapy for HER-2 negative metastatic breast cancer (MBC) prolongs progression-free survival without a substantial increase of toxicity. A Markov cohort simulation was used to follow the clinical course of typical patients with MBC. Information on response rates and major adverse effects was derived, and transition probabilities were estimated, based on the results of the E2100 clinical trial. Direct costs were assessed from the perspective of the Swiss health system. The addition of bevacizumab to weekly paclitaxel is estimated to cost an additional 40,369euro and to yield a gain of 0.22 quality-adjusted life years (QALYs), resulting in an incremental cost-effectiveness ratio of 189,427euro/QALY gained. Probabilistic sensitivity analysis showed that the willingness-to-pay threshold of 60,000euro was never reached. The addition of bevacizumab to paclitaxel in MBC patients is expensive given the clinical benefit in terms of QALYs gained.
Dedes
Konstantin J
KJ
Department of Gynecology, University Hospital of Zurich, Frauenklinkstrasse, 8091 Zurich, Switzerland.
Matter-Walstra
Klazien
K
Schwenkglenks
Matthias
M
Pestalozzi
Bernhard C
BC
Fink
Daniel
D
Brauchli
Peter
P
Szucs
Thomas D
TD
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics* / Q000627:therapeutic use; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D003198:Computer Simulation; D003362:Cost-Benefit Analysis; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D016527:Drug Costs; D005260:Female; D006801:Humans; D008390:Markov Chains; D018803:Models, Economic; D017239:Paclitaxel / Q000191:economics* / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D018719:Erb-b2 Receptor Tyrosine Kinases; D015996:Survival Rate; D013557:Switzerland
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases